Ersodetug

Phase 3Small molecule

RRezolute

Ersodetug is one of 24 small molecule programs targeting Hyperinsulinism. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HyperinsulinismRecruiting

HypoglycemiaActive, not recruiting

HyperinsulinismPhase 3

Recruiting

HypoglycemiaPreclinical

Active, not recruiting

Competition

Competitive Landscape

25 competitors in Hypoglycemia

#DrugCompanyPhaseTrials

Aldactone

Pfizer

Approved

1 2

NOVOLIN R

Novo Nordisk

Approved

1 3

Avelox

Narcan

2 5

Symlin

AstraZeneca

Approved

1 6

Proglycem

Teva

Approved

1 7

Januvia

ZZydus Therapeutics Inc.

Approved

1 8

Luxiq

SSchering-Plough

Approved

1 9

Reglan

IIstituto Clinico Humanitas

Phase 2

1 10

Ersodetug

RRezolute

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 3Recruiting

Hyperinsulinism

NCT06881992

Clinical

Trials by Indication[1]

Hyperinsulinism2 trials

Intermediate-Size Cohort EAP for Ersodetug in Patients With Refractory Hypoglycemia Due to Tumor-Associated Hyperinsulinism (Tumor HI) Who Are Unable to Participate in a Clinical Trial

Available·RRezolute··NCT07262970

A Phase 3, Single-Arm, Open-label, Pivotal Study to Evaluate the Efficacy and Safety of Ersodetug Compared to Baseline in Patients With Inadequately Controlled Hypoglycemia Due to Tumor Hyperinsulinism (Tumor HI)

Recruiting·RRezolute·Phase 3·NCT06881992·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Ersodetug. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ersodetug compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ersodetug. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Rezolute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: RRezolute

Ersodetug

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Hyperinsulinism2 trials

References

Drug Info

Quick Facts

Related News